Fize Medical closes first tranche of $20m Series B target

Continuous fluid data for critical care

Fize Medical’s kUO system continuously measures urine output for clinicians caring for critically ill patients, providing a live signal in place of intermittent manual checks. Its planned Fize Optima platform is intended to use that data for AI-driven prediction and treatment guidance.

The company says the first close is part of a $20 million Series B target; the amount raised in this tranche was not disclosed. Fize plans to advance Optima and strengthen commercial activity in markets where its systems are available.

Use of funds

Accelerate development of Fize Optima for AI-driven prediction and treatment guidance

Strengthen commercial activities in leading markets

Funding history

Sep 18, 2026Series B · This roundUndisclosed

Sources

Similar rounds

All Healthtech rounds →

TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A · Oct 9, 2026

Arena

Provides crowdsourced AI model performance leaderboards

$200MSeries B · Oct 8, 2026

Preference Model

Reinforcement-learning environments that help AI labs train models to solve tasks without exploiting flaws in the grading system.

$16MSeed · Oct 7, 2026

Nous Research

Open-source AI models and the Hermes agent, which retains project memory and reusable skills across tasks.

$90MSeries B · Oct 7, 2026